In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are proud to announce the publication of the clinical trial “Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children.”. While Oral Rehydration (ORS) is the main treatment of acute diarrhea in children, the addition of specific antidiarrheals may speed up the reduction of symptoms. In this clinical trial, children receiving xyloglucan/gelose (vegetal ingredients of Xilaplus AF) on top of the ORS, had significantly fewer diarrheic episodes than those who received ORS alone. The improvement of symptoms in the group on Xyloglucan/gelose was evident from 6 hours after the first dose.
New publication of a retrospective, observational study of Gelatin tannate versus other antidiarrheal medication in children with acute Gastroenteritis.
Gelsectan®, Noventure´s new medical device intended for IBS-D, was presented at Noventure´s stand during the 3rd Meeting of the Federation of Neurogastroenterology and Motility, from 29 August to 1 September 2018 in Amsterdam, The Netherlands.
